Nam RK - Search Results

1

Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4.

Cervi D, Pak B, Venier NA, Sugar LM, Nam RK, Fleshner NE, Klotz LH, Venkateswaran V. Cervi D, et al. Among authors: nam rk. BMC Cancer. 2010 Jun 4;10:258. doi: 10.1186/1471-2407-10-258. BMC Cancer. 2010. PMID: 20525356 Free PMC article.

2

Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset.

Nam RK, Klotz LH, Jewett MA, Danjoux C, Trachtenberg J. Nam RK, et al. Br J Urol. 1998 Jan;81(1):100-4. doi: 10.1046/j.1464-410x.1998.00523.x. Br J Urol. 1998. PMID: 9467484

3

Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis.

Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. Nam RK, et al. J Urol. 1999 May;161(5):1521-4. J Urol. 1999. PMID: 10210387

4

Radical prostatectomy as treatment for prostate cancer.

Jewett MA, Fleshner N, Klotz LH, Nam RK, Trachtenberg J. Jewett MA, et al. Among authors: nam rk. CMAJ. 2003 Jan 7;168(1):44-5. CMAJ. 2003. PMID: 12515785 Free PMC article. No abstract available.

5

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy.

Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S; Canadian Uro-Oncology Group. Klotz LH, et al. J Urol. 2003 Sep;170(3):791-4. doi: 10.1097/01.ju.0000081404.98273.fd. J Urol. 2003. PMID: 12913699 Clinical Trial.

6

Permanent flank bulge is a consequence of flank incision for radical nephrectomy in one half of patients.

Chatterjee S, Nam R, Fleshner N, Klotz L. Chatterjee S, et al. Urol Oncol. 2004 Jan-Feb;22(1):36-9. doi: 10.1016/S1078-1439(03)00099-1. Urol Oncol. 2004. PMID: 14969802

7

Variation in patterns of practice in diagnosing screen-detected prostate cancer.

Nam RK, Toi A, Trachtenberg J, Jewett MA, Klotz L, Fleshner N, Bagnell PS, Sweet J, Sugar L, Narod SA. Nam RK, et al. BJU Int. 2004 Dec;94(9):1239-44. doi: 10.1111/j.1464-410X.2004.05150.x. BJU Int. 2004. PMID: 15610097

8

The use of genetic markers to determine risk for prostate cancer at prostate biopsy.

Nam RK, Zhang WW, Jewett MA, Trachtenberg J, Klotz LH, Emami M, Sugar L, Sweet J, Toi A, Narod SA. Nam RK, et al. Clin Cancer Res. 2005 Dec 1;11(23):8391-7. doi: 10.1158/1078-0432.CCR-05-1226. Clin Cancer Res. 2005. PMID: 16322300

9

Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.

Nam RK, Toi A, Trachtenberg J, Klotz LH, Jewett MA, Emami M, Sugar L, Sweet J, Pond GR, Narod SA. Nam RK, et al. J Urol. 2006 Feb;175(2):489-94. doi: 10.1016/S0022-5347(05)00159-X. J Urol. 2006. PMID: 16406978

10

A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.

Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, Jewett MA, Narod SA. Nam RK, et al. J Urol. 2006 Apr;175(4):1291-7. doi: 10.1016/S0022-5347(05)00695-6. J Urol. 2006. PMID: 16515983

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters